LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

SDS-089 is a First of Class Intra-Nasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Our Solution

SDS-089 provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects

Commercialization

LTR Pharma is commercializing a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SDS-089 with fast-track US NDA Filing within 2 years

322M

worldwide expected cases by 2025

10

minute effectiveness

$7.10B

projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.

ON DEMAND
SOLUTION

LTR Pharma Couple

RAPID ONSET
ACTION

BRING BACK
SPONTANIETY

With a clear commercial pathway to disrupt the established PDE5 market

Contact Us

  • If other, please provide details
  • This field is for validation purposes and should be left unchanged.